Exact Mass: 519.0744

Exact Mass Matches: 519.0744

Found 45 metabolites which its exact mass value is equals to given mass value 519.0744, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Pelargonidin 3-(6'-malonylglucoside)

3-{[(2S,3R,4S,5S,6R)-6-{[(2-carboxyacetyl)oxy]methyl}-3,4,5-trihydroxyoxan-2-yl]oxy}-5,7-dihydroxy-2-(4-hydroxyphenyl)-1lambda4-chromen-1-ylium

C24H23O13+ (519.1139)


Pelargonidin 3-(6-malonylglucoside) is a member of the class of compounds known as anthocyanidin-3-o-glycosides. Anthocyanidin-3-o-glycosides are phenolic compounds containing one anthocyanidin moiety which is O-glycosidically linked to a carbohydrate moiety at the C3-position. Pelargonidin 3-(6-malonylglucoside) is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Pelargonidin 3-(6-malonylglucoside) can be found in cloudberry, lupine, red raspberry, and strawberry, which makes pelargonidin 3-(6-malonylglucoside) a potential biomarker for the consumption of these food products.

   

Ceforanide

(6R,7R)-7-{2-[2-(aminomethyl)phenyl]acetamido}-3-({[1-(carboxymethyl)-1H-1,2,3,4-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

C20H21N7O6S2 (519.0995)


Ceforanide is a second-generation parenteral cephalosporin antibiotic. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, a second-generation cephalosporin, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DC - Second-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

   

Cefminox

7-{2-[(2-amino-2-carboxyethyl)sulfanyl]acetamido}-7-methoxy-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

C16H21N7O7S3 (519.0665)


   

Dabrafenib

N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene-1-sulfonamide

C23H20F3N5O2S2 (519.101)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EC - B-raf serine-threonine kinase (braf) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2336 - Raf Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively[4].

   
   
   

Pelargonidin 3-(6-malonylglucoside)

3- [ [ 6-O- (1,3-Dioxo-3-hydroxypropyl) -beta-D-glucopyranosyl ] oxy ] -4,5,7-trihydroxyflavylium

C24H23O13 (519.1139)


   
   

Dabrafenib

Dabrafenib

C23H20F3N5O2S2 (519.101)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EC - B-raf serine-threonine kinase (braf) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2336 - Raf Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively[4].

   
   

Pelargonidin-3-(6-malonylglucoside)

Pelargonidin-3-(6-malonylglucoside)

[C24H23O13]+ (519.1139)


   
   

Suproclone

Suproclone

C22H22ClN5O4S2 (519.0802)


C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic

   

5-(6-(BENZYLOXY)-5-IODONAPHTHALEN-2-YL)-2,2-DIMETHYL-5-NITRO-1,3-DIOXANE

5-(6-(BENZYLOXY)-5-IODONAPHTHALEN-2-YL)-2,2-DIMETHYL-5-NITRO-1,3-DIOXANE

C23H22INO5 (519.0543)


   

Capadenoson

Capadenoson

C25H18ClN5O2S2 (519.059)


Capadenoson is a selective agonist of adenosine-A1 receptor.

   

α,β-Methylene-ATP dilithium

α,β-Methylene-ATP dilithium

C11H18Li2N5O12P3 (519.0485)


   
   

Sulfamic acid, [(1R,2R,3S,4R)-2,3-dihydroxy-4-[[2-[3-[(trifluoromethyl)thio]phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]amino]cyclopentyl]methyl ester

Sulfamic acid, [(1R,2R,3S,4R)-2,3-dihydroxy-4-[[2-[3-[(trifluoromethyl)thio]phenyl]pyrazolo[1,5-a]pyrimidin-7-yl]amino]cyclopentyl]methyl ester

C19H20F3N5O5S2 (519.0858)


C471 - Enzyme Inhibitor

   

Cefminox

Cefminox

C16H21N7O7S3 (519.0665)


J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DC - Second-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002513 - Cephamycins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

   

Pradefovir Mesylate

Pradefovir Mesylate

C18H23ClN5O7PS (519.0744)


D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C254 - Anti-Infective Agent > C281 - Antiviral Agent

   

Mycobacterium Tuberculosis Inhibitor

Mycobacterium Tuberculosis Inhibitor

C26H21N3O5S2 (519.0923)


   
   

4-CDP-2-C-methyl-D-erythritol(2-)

4-CDP-2-C-methyl-D-erythritol(2-)

C14H23N3O14P2-2 (519.0655)


   

(2R)-2-[(2,3-dihydroxybenzoyl)amino]-3-[(2S)-2-[(2,3-dihydroxybenzoyl)amino]-3-hydroxypropanoyl]oxypropanoate;iron

(2R)-2-[(2,3-dihydroxybenzoyl)amino]-3-[(2S)-2-[(2,3-dihydroxybenzoyl)amino]-3-hydroxypropanoyl]oxypropanoate;iron

C20H19FeN2O11- (519.0338)


   

2-Thioxo-4-oxo-5-[3-[(alpha-methylbenzyl)oxy]-4-(phenethyloxy)benzylidene]thiazolidine-3-acetic acid

2-Thioxo-4-oxo-5-[3-[(alpha-methylbenzyl)oxy]-4-(phenethyloxy)benzylidene]thiazolidine-3-acetic acid

C28H25NO5S2 (519.1174)


   

Fe(III)-[N-(2,3-dihydroxybenzoyl)-L-serine]2

Fe(III)-[N-(2,3-dihydroxybenzoyl)-L-serine]2

C20H19FeN2O11- (519.0338)


   

(2S)-naringenin 7-O-(6-O-malonyl-beta-D-glucoside)

(2S)-naringenin 7-O-(6-O-malonyl-beta-D-glucoside)

C24H23O13- (519.1139)


   
   

(6R,7S)-7-[[2-[2-(aminomethyl)phenyl]-1-oxoethyl]amino]-3-[[[1-(carboxymethyl)-5-tetrazolyl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

(6R,7S)-7-[[2-[2-(aminomethyl)phenyl]-1-oxoethyl]amino]-3-[[[1-(carboxymethyl)-5-tetrazolyl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

C20H21N7O6S2 (519.0995)


   

3-[2-[(E,3E)-3-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)-2-methoxyprop-1-enyl]-1,3-benzothiazol-3-ium-3-yl]propane-1-sulfonic acid

3-[2-[(E,3E)-3-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)-2-methoxyprop-1-enyl]-1,3-benzothiazol-3-ium-3-yl]propane-1-sulfonic acid

C24H27N2O5S3+ (519.1082)


   

Pelargonidin 3-(6-malonylglucoside)

Pelargonidin 3-O-(6-O-malonyl-beta-D-glucoside)

C24H23O13+ (519.1139)


   

Ceforanide

Ceforanide

C20H21N7O6S2 (519.0995)


A second-generation cephalosporin antibiotic with {[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and 2-(aminomethyl)phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is effective against many coliforms, including Escherichia coli, Klebsiella, Enterobacter and Proteus, and most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DC - Second-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

   

4-CDP-2-C-methyl-D-erythritol(2-)

4-CDP-2-C-methyl-D-erythritol(2-)

C14H23N3O14P2 (519.0655)


Dianion of 4-CDP-2-C-methyl-D-erythritol arising from deprotonation of the diphosphate OH groups; major species at pH 7.3.

   

(2r)-3-[(4a,8,12a,12b-tetrahydroxy-3-methyl-1,7,12-trioxo-5,6-dihydro-4h-tetraphen-6a-yl)sulfanyl]-2-[(1-hydroxyethylidene)amino]propanoic acid

(2r)-3-[(4a,8,12a,12b-tetrahydroxy-3-methyl-1,7,12-trioxo-5,6-dihydro-4h-tetraphen-6a-yl)sulfanyl]-2-[(1-hydroxyethylidene)amino]propanoic acid

C24H25NO10S (519.1199)


   
   

Aristoloside

aristoloside

C23H21NO13 (519.1013)


{"Ingredient_id": "HBIN016829","Ingredient_name": "Aristoloside","Alias": "aristoloside","Ingredient_formula": "C23H21NO13","Ingredient_Smile": "COC1=CC(=CC2=C3C(=C(C=C12)[N+](=O)[O-])C(=CC4=C3OCO4)C(=O)O)OC5C(C(C(C(O5)CO)O)O)O","Ingredient_weight": "519.41","OB_score": "3.865093461","CAS_id": "84014-70-0","SymMap_id": "SMIT11792","TCMID_id": "1725","TCMSP_id": "MOL010802","TCM_ID_id": "6651","PubChem_id": "128576","DrugBank_id": "NA"}

   

3-{[(2s,3r,4r,5s,6r)-6-{[(2-carboxyacetyl)oxy]methyl}-3,4,5-trihydroxyoxan-2-yl]oxy}-5,7-dihydroxy-2-(4-hydroxyphenyl)-1λ⁴-chromen-1-ylium

3-{[(2s,3r,4r,5s,6r)-6-{[(2-carboxyacetyl)oxy]methyl}-3,4,5-trihydroxyoxan-2-yl]oxy}-5,7-dihydroxy-2-(4-hydroxyphenyl)-1λ⁴-chromen-1-ylium

[C24H23O13]+ (519.1139)


   

(2s)-n-(3-{[2-(2,4-dibromo-5-methoxyphenyl)ethyl](methyl)amino}propyl)-2-(dimethylamino)-4-methylpentanimidic acid

(2s)-n-(3-{[2-(2,4-dibromo-5-methoxyphenyl)ethyl](methyl)amino}propyl)-2-(dimethylamino)-4-methylpentanimidic acid

C21H35Br2N3O2 (519.1096)


   

3-{[(2s,5s)-6-{[(2-carboxyacetyl)oxy]methyl}-3,4,5-trihydroxyoxan-2-yl]oxy}-5,7-dihydroxy-2-(4-hydroxyphenyl)-1λ⁴-chromen-1-ylium

3-{[(2s,5s)-6-{[(2-carboxyacetyl)oxy]methyl}-3,4,5-trihydroxyoxan-2-yl]oxy}-5,7-dihydroxy-2-(4-hydroxyphenyl)-1λ⁴-chromen-1-ylium

[C24H23O13]+ (519.1139)


   

(6r,7r)-7-({2-[2-(aminomethyl)phenyl]-1-hydroxyethylidene}amino)-3-({[1-(carboxymethyl)-1,2,3,4-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

(6r,7r)-7-({2-[2-(aminomethyl)phenyl]-1-hydroxyethylidene}amino)-3-({[1-(carboxymethyl)-1,2,3,4-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

C20H21N7O6S2 (519.0995)


   

n-(3-{[2-(2,4-dibromo-5-methoxyphenyl)ethyl](methyl)amino}propyl)-2-(dimethylamino)-4-methylpentanimidic acid

n-(3-{[2-(2,4-dibromo-5-methoxyphenyl)ethyl](methyl)amino}propyl)-2-(dimethylamino)-4-methylpentanimidic acid

C21H35Br2N3O2 (519.1096)


   

n-(3-{[2-(2,4-dibromo-5-methoxyphenyl)ethyl](methyl)amino}propyl)-2-(dimethylamino)-3-methylpentanimidic acid

n-(3-{[2-(2,4-dibromo-5-methoxyphenyl)ethyl](methyl)amino}propyl)-2-(dimethylamino)-3-methylpentanimidic acid

C21H35Br2N3O2 (519.1096)


   

3-{[(2s,3r,4s,5s,6r)-6-{[(2-carboxyacetyl)oxy]methyl}-3,4,5-trihydroxyoxan-2-yl]oxy}-5,7-dihydroxy-2-(4-hydroxyphenyl)-1λ⁴-chromen-1-ylium

3-{[(2s,3r,4s,5s,6r)-6-{[(2-carboxyacetyl)oxy]methyl}-3,4,5-trihydroxyoxan-2-yl]oxy}-5,7-dihydroxy-2-(4-hydroxyphenyl)-1λ⁴-chromen-1-ylium

[C24H23O13]+ (519.1139)


   

8-methoxy-6-nitro-10-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2h-phenanthro[3,4-d][1,3]dioxole-5-carboxylic acid

8-methoxy-6-nitro-10-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2h-phenanthro[3,4-d][1,3]dioxole-5-carboxylic acid

C23H21NO13 (519.1013)


   

(2s,3s)-n-(3-{[2-(2,4-dibromo-5-methoxyphenyl)ethyl](methyl)amino}propyl)-2-(dimethylamino)-3-methylpentanimidic acid

(2s,3s)-n-(3-{[2-(2,4-dibromo-5-methoxyphenyl)ethyl](methyl)amino}propyl)-2-(dimethylamino)-3-methylpentanimidic acid

C21H35Br2N3O2 (519.1096)